A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus
A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted and nine studies were identified in different countries. Due to the heterogeneity among these studies in terms of modeling approach, vaccination strategies, health outcomes considered, assumptions and paramete...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2013-11, Vol.9 (11), p.2285-2295 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2295 |
|---|---|
| container_issue | 11 |
| container_start_page | 2285 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 9 |
| creator | Jiang, Yiling Gauthier, Aline Postma, Maarten J Ribassin-Majed, Laureen Largeron, Nathalie Bresse, Xavier |
| description | A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted and nine studies were identified in different countries. Due to the heterogeneity among these studies in terms of modeling approach, vaccination strategies, health outcomes considered, assumptions and parameters, limited conclusions can be drawn with regard to the absolute cost-effectiveness. Nevertheless, key drivers were identified. More favorable cost-effectiveness appeared when all HPV-related diseases outcomes were considered, a suboptimal vaccine coverage among girls and/or lower vaccine prices were assumed. There was a general lack of transparency to fully describe the details of the methodological approach of modeling and calibration. Further research should be conducted to generate robust evidence-based data sets (HPV-related diseases epidemiology, costs and quality of life). The best modeling practice for HPV vaccination and how to better capture the true economic value of vaccination beyond cost-effectiveness in a broader policy context need to be investigated. |
| doi_str_mv | 10.4161/hv.25754 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_23880955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1524816933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-8563a4d0d7a1992a91d046d61743b8092048e44b1e6f1b02d6acd8240545cba43</originalsourceid><addsrcrecordid>eNplkUtr3DAURkVpaEIS6C8oXrYLp3qPvCkMIW0KA900kJ24luWxiixNJdlh_n09nXT60kbi3qNzJT6EXhN8w4kk74f5hoqV4C_QBSWS10Lwx5enMxHn6Drnb3hZK0y5lK_QOWVK4UaIC9SuK5NccQZ8lezs7FMV-8rEXGrb99YUN9tgc64ggN9nmw_tGYxxAYoL22oEvxRhCy7kUg3TCKHawc55H0eYXZryFTrrwWd7_bxfooePd19v7-vNl0-fb9eb2nCBS62EZMA73K2ANA2FhnSYy06SFWft8lqKubKct8TKnrSYdhJMpyjHggvTAmeX6MPRu5va0XbGhpLA611yI6S9juD0353gBr2Ns2aNIoqJRfDuKBj-uXa_3uhDDWMlqWjkTBb27fOwFL9PNhc9umys9xBsnLImgnJFZMPYb9SkmHOy_clNsD4kqIdZ_0xwQd_8-YUT-CuvBWBHwIU-phGeYvKdLrD3MfUJgnFZs_-0PwCqOqjg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1524816933</pqid></control><display><type>article</type><title>A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Jiang, Yiling ; Gauthier, Aline ; Postma, Maarten J ; Ribassin-Majed, Laureen ; Largeron, Nathalie ; Bresse, Xavier</creator><creatorcontrib>Jiang, Yiling ; Gauthier, Aline ; Postma, Maarten J ; Ribassin-Majed, Laureen ; Largeron, Nathalie ; Bresse, Xavier</creatorcontrib><description>A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted and nine studies were identified in different countries. Due to the heterogeneity among these studies in terms of modeling approach, vaccination strategies, health outcomes considered, assumptions and parameters, limited conclusions can be drawn with regard to the absolute cost-effectiveness. Nevertheless, key drivers were identified. More favorable cost-effectiveness appeared when all HPV-related diseases outcomes were considered, a suboptimal vaccine coverage among girls and/or lower vaccine prices were assumed. There was a general lack of transparency to fully describe the details of the methodological approach of modeling and calibration. Further research should be conducted to generate robust evidence-based data sets (HPV-related diseases epidemiology, costs and quality of life). The best modeling practice for HPV vaccination and how to better capture the true economic value of vaccination beyond cost-effectiveness in a broader policy context need to be investigated.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.4161/hv.25754</identifier><identifier>PMID: 23880955</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Cost-Benefit Analysis ; cost-effectiveness ; economic evaluation ; Human health and pathology ; human papillomavirus ; Humans ; Infectious diseases ; Life Sciences ; Male ; males ; Models, Statistical ; Papillomavirus Infections - economics ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - prevention & control ; Papillomavirus Vaccines - administration & dosage ; Papillomavirus Vaccines - economics ; Papillomavirus Vaccines - immunology ; Review ; strategy ; Vaccination - economics ; Vaccination - statistics & numerical data ; vaccine</subject><ispartof>Human vaccines & immunotherapeutics, 2013-11, Vol.9 (11), p.2285-2295</ispartof><rights>Copyright © 2013 Landes Bioscience 2013</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-8563a4d0d7a1992a91d046d61743b8092048e44b1e6f1b02d6acd8240545cba43</citedby><cites>FETCH-LOGICAL-c450t-8563a4d0d7a1992a91d046d61743b8092048e44b1e6f1b02d6acd8240545cba43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981835/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981835/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23880955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00862596$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Yiling</creatorcontrib><creatorcontrib>Gauthier, Aline</creatorcontrib><creatorcontrib>Postma, Maarten J</creatorcontrib><creatorcontrib>Ribassin-Majed, Laureen</creatorcontrib><creatorcontrib>Largeron, Nathalie</creatorcontrib><creatorcontrib>Bresse, Xavier</creatorcontrib><title>A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted and nine studies were identified in different countries. Due to the heterogeneity among these studies in terms of modeling approach, vaccination strategies, health outcomes considered, assumptions and parameters, limited conclusions can be drawn with regard to the absolute cost-effectiveness. Nevertheless, key drivers were identified. More favorable cost-effectiveness appeared when all HPV-related diseases outcomes were considered, a suboptimal vaccine coverage among girls and/or lower vaccine prices were assumed. There was a general lack of transparency to fully describe the details of the methodological approach of modeling and calibration. Further research should be conducted to generate robust evidence-based data sets (HPV-related diseases epidemiology, costs and quality of life). The best modeling practice for HPV vaccination and how to better capture the true economic value of vaccination beyond cost-effectiveness in a broader policy context need to be investigated.</description><subject>Cost-Benefit Analysis</subject><subject>cost-effectiveness</subject><subject>economic evaluation</subject><subject>Human health and pathology</subject><subject>human papillomavirus</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Male</subject><subject>males</subject><subject>Models, Statistical</subject><subject>Papillomavirus Infections - economics</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Vaccines - administration & dosage</subject><subject>Papillomavirus Vaccines - economics</subject><subject>Papillomavirus Vaccines - immunology</subject><subject>Review</subject><subject>strategy</subject><subject>Vaccination - economics</subject><subject>Vaccination - statistics & numerical data</subject><subject>vaccine</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><recordid>eNplkUtr3DAURkVpaEIS6C8oXrYLp3qPvCkMIW0KA900kJ24luWxiixNJdlh_n09nXT60kbi3qNzJT6EXhN8w4kk74f5hoqV4C_QBSWS10Lwx5enMxHn6Drnb3hZK0y5lK_QOWVK4UaIC9SuK5NccQZ8lezs7FMV-8rEXGrb99YUN9tgc64ggN9nmw_tGYxxAYoL22oEvxRhCy7kUg3TCKHawc55H0eYXZryFTrrwWd7_bxfooePd19v7-vNl0-fb9eb2nCBS62EZMA73K2ANA2FhnSYy06SFWft8lqKubKct8TKnrSYdhJMpyjHggvTAmeX6MPRu5va0XbGhpLA611yI6S9juD0353gBr2Ns2aNIoqJRfDuKBj-uXa_3uhDDWMlqWjkTBb27fOwFL9PNhc9umys9xBsnLImgnJFZMPYb9SkmHOy_clNsD4kqIdZ_0xwQd_8-YUT-CuvBWBHwIU-phGeYvKdLrD3MfUJgnFZs_-0PwCqOqjg</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Jiang, Yiling</creator><creator>Gauthier, Aline</creator><creator>Postma, Maarten J</creator><creator>Ribassin-Majed, Laureen</creator><creator>Largeron, Nathalie</creator><creator>Bresse, Xavier</creator><general>Taylor & Francis</general><general>Landes Bioscience</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope></search><sort><creationdate>20131101</creationdate><title>A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus</title><author>Jiang, Yiling ; Gauthier, Aline ; Postma, Maarten J ; Ribassin-Majed, Laureen ; Largeron, Nathalie ; Bresse, Xavier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-8563a4d0d7a1992a91d046d61743b8092048e44b1e6f1b02d6acd8240545cba43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Cost-Benefit Analysis</topic><topic>cost-effectiveness</topic><topic>economic evaluation</topic><topic>Human health and pathology</topic><topic>human papillomavirus</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Male</topic><topic>males</topic><topic>Models, Statistical</topic><topic>Papillomavirus Infections - economics</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Vaccines - administration & dosage</topic><topic>Papillomavirus Vaccines - economics</topic><topic>Papillomavirus Vaccines - immunology</topic><topic>Review</topic><topic>strategy</topic><topic>Vaccination - economics</topic><topic>Vaccination - statistics & numerical data</topic><topic>vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Yiling</creatorcontrib><creatorcontrib>Gauthier, Aline</creatorcontrib><creatorcontrib>Postma, Maarten J</creatorcontrib><creatorcontrib>Ribassin-Majed, Laureen</creatorcontrib><creatorcontrib>Largeron, Nathalie</creatorcontrib><creatorcontrib>Bresse, Xavier</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Yiling</au><au>Gauthier, Aline</au><au>Postma, Maarten J</au><au>Ribassin-Majed, Laureen</au><au>Largeron, Nathalie</au><au>Bresse, Xavier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>9</volume><issue>11</issue><spage>2285</spage><epage>2295</epage><pages>2285-2295</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted and nine studies were identified in different countries. Due to the heterogeneity among these studies in terms of modeling approach, vaccination strategies, health outcomes considered, assumptions and parameters, limited conclusions can be drawn with regard to the absolute cost-effectiveness. Nevertheless, key drivers were identified. More favorable cost-effectiveness appeared when all HPV-related diseases outcomes were considered, a suboptimal vaccine coverage among girls and/or lower vaccine prices were assumed. There was a general lack of transparency to fully describe the details of the methodological approach of modeling and calibration. Further research should be conducted to generate robust evidence-based data sets (HPV-related diseases epidemiology, costs and quality of life). The best modeling practice for HPV vaccination and how to better capture the true economic value of vaccination beyond cost-effectiveness in a broader policy context need to be investigated.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>23880955</pmid><doi>10.4161/hv.25754</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2013-11, Vol.9 (11), p.2285-2295 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_pubmed_primary_23880955 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Cost-Benefit Analysis cost-effectiveness economic evaluation Human health and pathology human papillomavirus Humans Infectious diseases Life Sciences Male males Models, Statistical Papillomavirus Infections - economics Papillomavirus Infections - epidemiology Papillomavirus Infections - prevention & control Papillomavirus Vaccines - administration & dosage Papillomavirus Vaccines - economics Papillomavirus Vaccines - immunology Review strategy Vaccination - economics Vaccination - statistics & numerical data vaccine |
| title | A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T22%3A02%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20critical%20review%20of%20cost-effectiveness%20analyses%20of%20vaccinating%20males%20against%20human%20papillomavirus&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Jiang,%20Yiling&rft.date=2013-11-01&rft.volume=9&rft.issue=11&rft.spage=2285&rft.epage=2295&rft.pages=2285-2295&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.4161/hv.25754&rft_dat=%3Cproquest_pubme%3E1524816933%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1524816933&rft_id=info:pmid/23880955&rfr_iscdi=true |